nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.141	0.215	CbGbCtD
Linagliptin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0955	0.145	CbGbCtD
Linagliptin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0911	0.139	CbGbCtD
Linagliptin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0812	0.124	CbGbCtD
Linagliptin—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0796	0.121	CbGbCtD
Linagliptin—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0751	0.114	CbGbCtD
Linagliptin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0477	0.0726	CbGbCtD
Linagliptin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.045	0.0685	CbGbCtD
Linagliptin—Bronchial hyperreactivity—Aminophylline—chronic obstructive pulmonary disease	0.0191	0.0579	CcSEcCtD
Linagliptin—Pancreatitis acute—Roflumilast—chronic obstructive pulmonary disease	0.0162	0.0491	CcSEcCtD
Linagliptin—Hyperlipidaemia—Arformoterol—chronic obstructive pulmonary disease	0.00527	0.016	CcSEcCtD
Linagliptin—Hyperlipidaemia—Formoterol—chronic obstructive pulmonary disease	0.00527	0.016	CcSEcCtD
Linagliptin—Skin exfoliation—Aminophylline—chronic obstructive pulmonary disease	0.00477	0.0144	CcSEcCtD
Linagliptin—Infestation NOS—Roflumilast—chronic obstructive pulmonary disease	0.00419	0.0127	CcSEcCtD
Linagliptin—Infestation—Roflumilast—chronic obstructive pulmonary disease	0.00419	0.0127	CcSEcCtD
Linagliptin—Urinary tract infection—Roflumilast—chronic obstructive pulmonary disease	0.00407	0.0123	CcSEcCtD
Linagliptin—Pain in extremity—Tiotropium—chronic obstructive pulmonary disease	0.00342	0.0103	CcSEcCtD
Linagliptin—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.0034	0.0103	CcSEcCtD
Linagliptin—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00339	0.0103	CcSEcCtD
Linagliptin—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00327	0.00991	CcSEcCtD
Linagliptin—Pancreatitis acute—Prednisone—chronic obstructive pulmonary disease	0.00324	0.00981	CcSEcCtD
Linagliptin—Back pain—Roflumilast—chronic obstructive pulmonary disease	0.00317	0.00959	CcSEcCtD
Linagliptin—Diabetes mellitus—Salbutamol—chronic obstructive pulmonary disease	0.003	0.00907	CcSEcCtD
Linagliptin—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.00299	0.00905	CcSEcCtD
Linagliptin—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00283	0.00856	CcSEcCtD
Linagliptin—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00283	0.00856	CcSEcCtD
Linagliptin—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.00279	0.00844	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00277	0.00838	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Tiotropium—chronic obstructive pulmonary disease	0.00275	0.00831	CcSEcCtD
Linagliptin—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00267	0.00808	CcSEcCtD
Linagliptin—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00265	0.00803	CcSEcCtD
Linagliptin—Hypertriglyceridaemia—Prednisone—chronic obstructive pulmonary disease	0.0026	0.00788	CcSEcCtD
Linagliptin—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0026	0.00786	CcSEcCtD
Linagliptin—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.00256	0.00775	CcSEcCtD
Linagliptin—Nasopharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.00247	0.00747	CcSEcCtD
Linagliptin—Nasopharyngitis—Formoterol—chronic obstructive pulmonary disease	0.00247	0.00747	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00243	0.00737	CcSEcCtD
Linagliptin—Nasopharyngitis—Montelukast—chronic obstructive pulmonary disease	0.00242	0.00731	CcSEcCtD
Linagliptin—Nasopharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.00233	0.00705	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00231	0.00698	CcSEcCtD
Linagliptin—Pancreatitis—Montelukast—chronic obstructive pulmonary disease	0.00229	0.00693	CcSEcCtD
Linagliptin—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00228	0.00692	CcSEcCtD
Linagliptin—Blood triglycerides increased—Prednisone—chronic obstructive pulmonary disease	0.00228	0.00691	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00222	0.00671	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Formoterol—chronic obstructive pulmonary disease	0.00222	0.00671	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Montelukast—chronic obstructive pulmonary disease	0.00217	0.00657	CcSEcCtD
Linagliptin—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00214	0.00647	CcSEcCtD
Linagliptin—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00213	0.00645	CcSEcCtD
Linagliptin—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00212	0.00642	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00209	0.00633	CcSEcCtD
Linagliptin—Infestation—Montelukast—chronic obstructive pulmonary disease	0.00208	0.0063	CcSEcCtD
Linagliptin—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.00208	0.0063	CcSEcCtD
Linagliptin—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.00207	0.00626	CcSEcCtD
Linagliptin—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.00207	0.00626	CcSEcCtD
Linagliptin—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00206	0.00623	CcSEcCtD
Linagliptin—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.00199	0.00603	CcSEcCtD
Linagliptin—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00197	0.00596	CcSEcCtD
Linagliptin—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.00195	0.00591	CcSEcCtD
Linagliptin—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.00188	0.00569	CcSEcCtD
Linagliptin—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00183	0.00553	CcSEcCtD
Linagliptin—Cough—Tiotropium—chronic obstructive pulmonary disease	0.0018	0.00544	CcSEcCtD
Linagliptin—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00178	0.00539	CcSEcCtD
Linagliptin—Infection—Aminophylline—chronic obstructive pulmonary disease	0.00177	0.00536	CcSEcCtD
Linagliptin—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.00175	0.00531	CcSEcCtD
Linagliptin—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00175	0.00531	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00174	0.00527	CcSEcCtD
Linagliptin—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00172	0.00522	CcSEcCtD
Linagliptin—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00172	0.00522	CcSEcCtD
Linagliptin—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00172	0.00521	CcSEcCtD
Linagliptin—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00172	0.00521	CcSEcCtD
Linagliptin—Diabetes mellitus—Prednisolone—chronic obstructive pulmonary disease	0.00172	0.0052	CcSEcCtD
Linagliptin—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00169	0.00511	CcSEcCtD
Linagliptin—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00168	0.0051	CcSEcCtD
Linagliptin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00168	0.0051	CcSEcCtD
Linagliptin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00168	0.00509	CcSEcCtD
Linagliptin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00167	0.00507	CcSEcCtD
Linagliptin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00167	0.00505	CcSEcCtD
Linagliptin—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00166	0.00503	CcSEcCtD
Linagliptin—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00166	0.00503	CcSEcCtD
Linagliptin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00163	0.00494	CcSEcCtD
Linagliptin—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00163	0.00493	CcSEcCtD
Linagliptin—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00162	0.00492	CcSEcCtD
Linagliptin—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.00161	0.00486	CcSEcCtD
Linagliptin—Back pain—Formoterol—chronic obstructive pulmonary disease	0.00161	0.00486	CcSEcCtD
Linagliptin—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00157	0.00475	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00153	0.00463	CcSEcCtD
Linagliptin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00152	0.0046	CcSEcCtD
Linagliptin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.0046	CcSEcCtD
Linagliptin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00459	CcSEcCtD
Linagliptin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00149	0.0045	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00145	0.00439	CcSEcCtD
Linagliptin—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00439	CcSEcCtD
Linagliptin—Cough—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00439	CcSEcCtD
Linagliptin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00144	0.00435	CcSEcCtD
Linagliptin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00434	CcSEcCtD
Linagliptin—Skin exfoliation—Prednisone—chronic obstructive pulmonary disease	0.00143	0.00432	CcSEcCtD
Linagliptin—Cough—Montelukast—chronic obstructive pulmonary disease	0.00142	0.0043	CcSEcCtD
Linagliptin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00142	0.00428	CcSEcCtD
Linagliptin—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00141	0.00428	CcSEcCtD
Linagliptin—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.00141	0.00428	CcSEcCtD
Linagliptin—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.00141	0.00428	CcSEcCtD
Linagliptin—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00141	0.00428	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.0014	0.00425	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.00425	CcSEcCtD
Linagliptin—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00419	CcSEcCtD
Linagliptin—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00419	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00138	0.00417	CcSEcCtD
Linagliptin—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00414	CcSEcCtD
Linagliptin—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00136	0.0041	CcSEcCtD
Linagliptin—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00136	0.0041	CcSEcCtD
Linagliptin—Infection—Formoterol—chronic obstructive pulmonary disease	0.00135	0.00408	CcSEcCtD
Linagliptin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00135	0.00408	CcSEcCtD
Linagliptin—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00404	CcSEcCtD
Linagliptin—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00404	CcSEcCtD
Linagliptin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00133	0.00404	CcSEcCtD
Linagliptin—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00133	0.00402	CcSEcCtD
Linagliptin—Infection—Montelukast—chronic obstructive pulmonary disease	0.00132	0.00399	CcSEcCtD
Linagliptin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00132	0.00399	CcSEcCtD
Linagliptin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00132	0.00399	CcSEcCtD
Linagliptin—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.00397	CcSEcCtD
Linagliptin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00129	0.00391	CcSEcCtD
Linagliptin—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00128	0.00388	CcSEcCtD
Linagliptin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.00127	0.00385	CcSEcCtD
Linagliptin—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.00127	0.00383	CcSEcCtD
Linagliptin—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.00125	0.00378	CcSEcCtD
Linagliptin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00124	0.00376	CcSEcCtD
Linagliptin—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00124	0.00375	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00124	0.00374	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.00124	0.00374	CcSEcCtD
Linagliptin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00122	0.00369	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—LEP—chronic obstructive pulmonary disease	0.00122	0.094	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00121	0.00366	CcSEcCtD
Linagliptin—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0012	0.0926	CbGpPWpGaD
Linagliptin—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.00118	0.00356	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00117	0.00354	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00117	0.00354	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00117	0.00353	CcSEcCtD
Linagliptin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00116	0.00351	CcSEcCtD
Linagliptin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00116	0.00351	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00115	0.00347	CcSEcCtD
Linagliptin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00112	0.0034	CcSEcCtD
Linagliptin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00112	0.0034	CcSEcCtD
Linagliptin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00112	0.00338	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00111	0.00335	CcSEcCtD
Linagliptin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00109	0.00331	CcSEcCtD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—LEP—chronic obstructive pulmonary disease	0.00108	0.0836	CbGpPWpGaD
Linagliptin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.00108	0.00326	CcSEcCtD
Linagliptin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.00108	0.00326	CcSEcCtD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00106	0.0818	CbGpPWpGaD
Linagliptin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.00321	CcSEcCtD
Linagliptin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00106	0.0032	CcSEcCtD
Linagliptin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00106	0.00319	CcSEcCtD
Linagliptin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00105	0.00319	CcSEcCtD
Linagliptin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00102	0.00308	CcSEcCtD
Linagliptin—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000999	0.00302	CcSEcCtD
Linagliptin—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000999	0.00302	CcSEcCtD
Linagliptin—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000979	0.00296	CcSEcCtD
Linagliptin—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000943	0.00286	CcSEcCtD
Linagliptin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000928	0.00281	CcSEcCtD
Linagliptin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000928	0.00281	CcSEcCtD
Linagliptin—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.00092	0.00279	CcSEcCtD
Linagliptin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000909	0.00275	CcSEcCtD
Linagliptin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000876	0.00265	CcSEcCtD
Linagliptin—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.000867	0.0669	CbGpPWpGaD
Linagliptin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000855	0.00259	CcSEcCtD
Linagliptin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000855	0.00259	CcSEcCtD
Linagliptin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000854	0.00259	CcSEcCtD
Linagliptin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000854	0.00259	CcSEcCtD
Linagliptin—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000854	0.00259	CcSEcCtD
Linagliptin—Headache—Formoterol—chronic obstructive pulmonary disease	0.00085	0.00257	CcSEcCtD
Linagliptin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00085	0.00257	CcSEcCtD
Linagliptin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000837	0.00253	CcSEcCtD
Linagliptin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000837	0.00253	CcSEcCtD
Linagliptin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000832	0.00252	CcSEcCtD
Linagliptin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000822	0.00249	CcSEcCtD
Linagliptin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000807	0.00244	CcSEcCtD
Linagliptin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000807	0.00244	CcSEcCtD
Linagliptin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000802	0.00243	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000734	0.00222	CcSEcCtD
Linagliptin—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000678	0.00205	CcSEcCtD
Linagliptin—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000654	0.00198	CcSEcCtD
Linagliptin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000597	0.00181	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—ACE—chronic obstructive pulmonary disease	0.000591	0.0456	CbGpPWpGaD
Linagliptin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000583	0.00177	CcSEcCtD
Linagliptin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000557	0.00169	CcSEcCtD
Linagliptin—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000557	0.00169	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00167	CcSEcCtD
Linagliptin—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000541	0.00164	CcSEcCtD
Linagliptin—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000534	0.00162	CcSEcCtD
Linagliptin—Infection—Prednisone—chronic obstructive pulmonary disease	0.00053	0.0016	CcSEcCtD
Linagliptin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000518	0.00157	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000486	0.00147	CcSEcCtD
Linagliptin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000463	0.0014	CcSEcCtD
Linagliptin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000463	0.0014	CcSEcCtD
Linagliptin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00046	0.00139	CcSEcCtD
Linagliptin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000456	0.00138	CcSEcCtD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00044	0.034	CbGpPWpGaD
Linagliptin—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000424	0.00128	CcSEcCtD
Linagliptin—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000393	0.00119	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—LEP—chronic obstructive pulmonary disease	0.000367	0.0283	CbGpPWpGaD
Linagliptin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000365	0.00111	CcSEcCtD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000337	0.026	CbGpPWpGaD
Linagliptin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00102	CcSEcCtD
Linagliptin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000336	0.00102	CcSEcCtD
Linagliptin—Headache—Prednisone—chronic obstructive pulmonary disease	0.000334	0.00101	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—MUC5AC—chronic obstructive pulmonary disease	0.000285	0.022	CbGpPWpGaD
Linagliptin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000261	0.0202	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MUC1—chronic obstructive pulmonary disease	0.000242	0.0187	CbGpPWpGaD
Linagliptin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000227	0.0175	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000207	0.016	CbGpPWpGaD
Linagliptin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000202	0.0156	CbGpPWpGaD
Linagliptin—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000198	0.0153	CbGpPWpGaD
Linagliptin—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00019	0.0147	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000183	0.0141	CbGpPWpGaD
Linagliptin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000165	0.0127	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000158	0.0122	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00015	0.0116	CbGpPWpGaD
Linagliptin—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000138	0.0107	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000133	0.0103	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000126	0.00972	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.0096	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000116	0.00895	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000115	0.00887	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ACE—chronic obstructive pulmonary disease	0.000112	0.00861	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—PLAUR—chronic obstructive pulmonary disease	0.0001	0.00774	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	9.76e-05	0.00754	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	9.76e-05	0.00753	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	9.2e-05	0.0071	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	8.44e-05	0.00652	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	8.07e-05	0.00623	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	7.89e-05	0.00609	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	7.88e-05	0.00608	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	7.79e-05	0.00601	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	7.52e-05	0.00581	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	7.48e-05	0.00578	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP1—chronic obstructive pulmonary disease	7.16e-05	0.00553	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	7.09e-05	0.00547	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	6.97e-05	0.00538	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—LEP—chronic obstructive pulmonary disease	6.93e-05	0.00535	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	6.4e-05	0.00494	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	5.87e-05	0.00453	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	5.73e-05	0.00443	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	5.66e-05	0.00437	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	4.65e-05	0.00359	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CXCL8—chronic obstructive pulmonary disease	4.6e-05	0.00356	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	4.31e-05	0.00333	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	4.13e-05	0.00319	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.09e-05	0.00316	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.04e-05	0.00312	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	4.04e-05	0.00312	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	3.5e-05	0.0027	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.4e-05	0.00262	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.35e-05	0.00259	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	3.22e-05	0.00249	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	3.21e-05	0.00248	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	3e-05	0.00231	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.83e-05	0.00219	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.79e-05	0.00216	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.6e-05	0.00201	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.57e-05	0.00198	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.47e-05	0.00191	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.43e-05	0.00188	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.14e-05	0.00165	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	2.08e-05	0.0016	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.99e-05	0.00153	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.93e-05	0.00149	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.73e-05	0.00133	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.66e-05	0.00128	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.58e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.55e-05	0.0012	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.48e-05	0.00114	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.32e-05	0.00102	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.3e-05	0.00101	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.28e-05	0.000988	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.19e-05	0.000919	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.13e-05	0.000876	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.12e-05	0.000866	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	0.00079	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	9.94e-06	0.000768	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.43e-06	0.000728	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.86e-06	0.000607	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.76e-06	0.000599	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.23e-06	0.000558	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.99e-06	0.00054	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	6.91e-06	0.000534	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.85e-06	0.000529	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	6.31e-06	0.000487	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.81e-06	0.000449	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.85e-06	0.000374	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.78e-06	0.000369	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	4.66e-06	0.00036	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.45e-06	0.000344	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.45e-06	0.000344	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.22e-06	0.000326	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.87e-06	0.000222	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.74e-06	0.000212	CbGpPWpGaD
